whitepaper

Application note: Monitoring Aggregation of Antibody-Drug Conjugates

Posted: 30 July 2019 | | No comments yet

Prediction of Aggregation Propensity and Monitoring of Aggregation of Antibody-Drug Conjugates (ADC).

Innate Pharma has developed an antibody-drug conjugate (ADC) coupling technology. To validate the technology concept for clinical applications, the stability of unglycosylated SGN30 Q and S mutants coupled to the MMAE toxin by either one-step (SGN30 Q/S-linker-vcMMAE) or two-step technology (SGN30 Q/S-Linker-Click-Linker-vcMMAE) was compared to the first FDA-approved ADC, ADCETRIS® and evaluated. Utilizing the ProteoStat® Thermal Shift Assay, the temperatures of aggregation were determined and used to establish an aggregation propensity prediction ladder.











To read this Application note in full, please complete the form below. By clicking submit you confirm that you accept our terms and conditions and privacy policy.


*

*

*

*

*

*

*

*

This content is provided to you for free thanks to the kind support of our sponsors: Enzo Life Sciences

Send this to a friend